Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P

Open source

DOI: 10.5604/16652681.1198803
Published: 2016 May-Jun
Container: Annals of hepatology
Publisher: Not recorded
Open access: no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.5604/16652681.1198803,
  title = {Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.},
  author = {Jensen DM and Asselah T and Dieterich D and Foster GR and Sulkowski MS and Zeuzem S and Mantry P and Yoshida EM and Moreno C and Ouzan D and Wright M and Morano LE and Buynak R and Bourlière M and Hassanein T and Nishiguchi S and Kao JH and Omata M and Paik SW and Wong DK and Tam E and Kaita K and Feinman SV and Stern JO and Scherer J and Quinson AM and Voss F and Gallivan JP and Böcher WO and Ferenci P},
  year = {2016},
  journal = {Annals of hepatology},
  doi = {10.5604/16652681.1198803},
  url = {https://doi.org/10.5604/16652681.1198803}
}

RIS

TY  - JOUR
TI  - Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
AU  - Jensen DM
AU  - Asselah T
AU  - Dieterich D
AU  - Foster GR
AU  - Sulkowski MS
AU  - Zeuzem S
AU  - Mantry P
AU  - Yoshida EM
AU  - Moreno C
AU  - Ouzan D
AU  - Wright M
AU  - Morano LE
AU  - Buynak R
AU  - Bourlière M
AU  - Hassanein T
AU  - Nishiguchi S
AU  - Kao JH
AU  - Omata M
AU  - Paik SW
AU  - Wong DK
AU  - Tam E
AU  - Kaita K
AU  - Feinman SV
AU  - Stern JO
AU  - Scherer J
AU  - Quinson AM
AU  - Voss F
AU  - Gallivan JP
AU  - Böcher WO
AU  - Ferenci P
PY  - 2016
JO  - Annals of hepatology
DO  - 10.5604/16652681.1198803
UR  - https://doi.org/10.5604/16652681.1198803
ER  -

APA

DM, J., T, A., D, D., GR, F., MS, S., S, Z., P, M., EM, Y., C, M., D, O., M, W., LE, M., R, B., M, B., T, H., S, N., JH, K., M, O., SW, P., DK, W., E, T., K, K., SV, F., JO, S., J, S., AM, Q., F, V., JP, G., WO, B., & P, F. (2016). Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.. Annals of hepatology. https://doi.org/10.5604/16652681.1198803

Source records

pubmed · retrieved 2026-09-26T10:35:51.551Z
europe-pmc · retrieved 2026-09-26T10:35:51.569Z
doaj · retrieved 2026-09-26T10:35:51.535Z